Corapcioğlu Funda, Büyükkapu-Bay Sema, Binnetoğlu Köksal, Babaoğlu Abdulkadir, Anik Yonca, Tugay Melih
Department of Pediatrics, Kocaeli University Faculty of Medicine, Kocaeli, Turkey.
Turk J Pediatr. 2011 Mar-Apr;53(2):137-41.
Propranolol, a non-selective beta-blocker, has recently been introduced as a treatment for infantile hemangiomas. In this study, we evaluated the effect of propranolol in 12 infants with hemangioma. Twelve infants (9 girls) with a median age of 4.5 months were included in the study. All of the patients in the study group received short-term (1-9 weeks, median: 4 weeks) systemic corticosteroids as a first-line therapy. All patients received propranolol 2 mg/kg/day, divided into three doses. They were treated in an inpatient setting for the first 72 hours of the treatment. Vital signs, blood pressure and blood glucose were monitored. Propranolol treatment was given for 4-9 months (median: 5 months). In the study group, regression rate of the mean dimension of the lesion was 38% +/- 15 (range 15%-50, median 45%) at the 2nd month of therapy. Over 9 months, which was the maximum follow-up period, the regression rate of the mean dimension of the lesion was 55% +/- 31 (range 20%-80, median 50%). One patient had transient bradycardia, which improved spontaneously. No other side effect was observed in the study population. Propranolol appears to be an effective drug for infantile hemangiomas with good clinical tolerance. We suggest that propranolol is the preferable drug as the first-line therapy for infantile hemangiomas.
普萘洛尔，一种非选择性β受体阻滞剂，最近被引入用于治疗婴儿血管瘤。在本研究中，我们评估了普萘洛尔对12例血管瘤婴儿的疗效。12例婴儿（9名女孩）纳入研究，中位年龄为4.5个月。研究组所有患者均接受短期（1 - 9周，中位：4周）全身皮质类固醇作为一线治疗。所有患者均接受普萘洛尔2 mg/kg/天，分三次给药。治疗的前72小时在住院环境中进行。监测生命体征、血压和血糖。普萘洛尔治疗4 - 9个月（中位：5个月）。在研究组中，治疗第2个月时病变平均尺寸的消退率为38%±15（范围15% - 50%，中位45%）。在最长9个月的随访期内，病变平均尺寸的消退率为55%±31（范围20% - 80%，中位50%）。1例患者出现短暂性心动过缓，自行好转。研究人群中未观察到其他副作用。普萘洛尔似乎是治疗婴儿血管瘤的有效药物，临床耐受性良好。我们建议普萘洛尔作为婴儿血管瘤的一线治疗药物更为可取。
